Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Erlotinib Hydrochloride

Erlotinib Hydrochloride Sale

(Synonyms: 盐酸埃罗替尼; CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride) 目录号 : GC15600

An EGFR tyrosine kinase inhibitor

Erlotinib Hydrochloride Chemical Structure

Cas No.:183319-69-9

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥420.00
现货
1g
¥378.00
现货
5g
¥1,313.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

Erlotinib hydrochloride (the trade name Tarceva?) is a directly acting inhibitor of epidermal growth factor receptor (EGFR/HER-1) tyrosine kinase with an IC50 of 2 nM.

Epidermal growth factor receptor (EGFR) is one member of the ErbB family which includes EGFR (ErbB1), ErbB2, ErbB3 and ErbB4. The activation of EGFR is dependent on the binding of peptide growth factors to the receptor. In many carcinomas, the presence of EGFR mutation leads to the activation of EGFP, which causes cell proliferation and other cancer processes [1].

Selective inhibition of EGFR tyrosine kinase by erlotinib hydrochloride leads to the disruption of cancer growth and development which include cell migration, proliferation, angiogenesis, and apoptosis. For instance, erlotinib hydrochloride was shown to induce cell apoptosis and G0/G1 cell cycle arrest in hepatocellular cancer cells, Bxpc-3 and PANC-1 cells, thereby enhancing chemosensitivity towards cytostatics [2, 3].

In addition, this product is widely researched and used for the treatment of human advanced non-small cell lung cancer (NSCLC) [4]. In pancreatic cancer, erlotinib hydrochloride was also reported to exhibit an anti-tumour effect [5].

References:
1.  Melosky B. Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. Front Oncol 2014,4:244.
2.  Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, et al. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin 2015,36:614-626.
3.  Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005,43:661-669.
4.  Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol 2014,5:858-864.
5.  Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, et al. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer 2014,50:1909-1915.

实验参考方法

Cell experiment: [1]

Cell lines

Calu1 cells

Preparation method

The solubility of this compound in DMSO is <10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

1 µM, 24 hours

Applications

Cells were treated with single dose of erlotinib (1 µM, 24 hours), docetaxel (50 nM, 18 hours) or the combination of erlotinib and docetaxel. The greatest cell death was observed in the Txt->OSI-774->media sequence, while the cells treated with the OSI-774->Txt->media sequence resumed proliferation by 72hrs post-treatment. Cleaved PARP and Caspase-3 were detected in the sequence of Txt->OSI-774, and with simultaneous treatment, but not in the sequence of OSI-774->Txt. Further, cleaved PARP and Caspase-3 persisted to 72hrs after the Txt->OSI-774 treatment. These data support the previous results on sub-G1 cells, and molecularly demonstrate an apoptotic response.

Animal experiment: [2]

Animal models

Female, athymic, nu/nu-nuBR nude mice injected with H460a cells

Dosage form

Oral administration, 100mg/kg, daily for 3 weeks

Applications

Erlotinib had significant dose-dependent efficacy. In the 100mg/kg group there was growth inhibition of 61%. The other groups had the following growth inhibition: 25mg/kg: 46%; 12.5mg/kg: 36%; 6.25mg/kg: 28%. There were no partial or complete regressions.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Kimura T, Mahaffey C M, Pryde B J, et al. Apoptotic effects of the docetaxel→ OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells//Proc Am Soc Clin Oncol. 2004, 22: 7143.

[2] Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-cancer drugs, 2004, 15(5): 503-512.

化学性质

Cas No. 183319-69-9 SDF
别名 盐酸埃罗替尼; CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride
化学名 N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride
Canonical SMILES COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl
分子式 C22H24ClN3O4 分子量 429.91
溶解度 ≥ 6.44 mg/mL in DMSO with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.3261 mL 11.6303 mL 23.2607 mL
5 mM 0.4652 mL 2.3261 mL 4.6521 mL
10 mM 0.2326 mL 1.163 mL 2.3261 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: